LSN News › India

Business · India Bureau

Generic Encorafenib Approved in India, Expanding Affordable Cancer Treatment Options

India's drug regulator has approved a generic version of encorafenib, a targeted cancer therapy, marking a significant step toward improving accessibility of advanced melanoma treatment. The approval of the bioequivalent formulation is expected to reduce treatment costs for patients across the region.

LSN India · 16 November 2026

Generic Encorafenib Approved in India, Expanding Affordable Cancer Treatment Options

The Drugs Controller General of India (DCGI) has granted approval for an Abbreviated New Drug Application (ANDA) for a generic formulation of encorafenib, establishing therapeutic equivalence to the reference drug Mektovi Tablets (15 mg), originally developed by Array BioPharma Inc. This regulatory clearance permits domestic manufacturers to produce and distribute the generic version across Indian markets.

Encorafenib is a targeted therapy used primarily in the treatment of melanoma patients carrying specific BRAF mutations. The drug works by inhibiting abnormal protein signaling that drives cancer cell growth, offering improved clinical outcomes compared to conventional chemotherapy approaches. The approval of a generic alternative addresses a critical need for more accessible and affordable treatment options in India, where cancer incidence continues to rise.

Industry analysts expect the generic formulation to significantly reduce treatment costs, potentially making advanced cancer therapy accessible to a broader patient population. The approval also encourages competitive pricing in the pharmaceutical market, benefiting healthcare systems and individual patients across India and neighboring South Asian nations.

This development aligns with India's broader public health objectives to enhance access to oncology treatments. Healthcare providers and patient advocacy groups have consistently emphasized the importance of affordable generic medications in improving survival rates and quality of life for cancer patients throughout the region.